A multi-arm, phase I/II clinical trial of NBTXR3 activated by radiation therapy in combination with anti-PD1 antibody in lung, and head and neck cancer patients
Phase of Trial: Phase I/II
Latest Information Update: 28 Dec 2017
At a glance
- Drugs NBTXR 3 (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Nanobiotix
- 28 Dec 2017 Planned initiation date changed to 1 Apr 2018.
- 26 Dec 2017 According to a Nanobiotix media release, the first patient first visit in the potentially paradigm changing trial is expected in Q2 2018 with with first expected results in the summer of 2019.
- 26 Dec 2017 According to a Nanobiotix media release, the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) Application for NBTXR3 for the conduct of this trial. The trial will be led by coordinating investigator Tanguy Seiwert, M.D., of The University of Chicago Medical Center, and principal investigator Jared Weiss, M.D., of The University of North Carolina - Chapel Hill.